Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R F Schlenk

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Der Internist|November 11, 2011
[Current treatment options in acute myeloid leukemia]M Heuser, R F Schlenk, A Ganser
Der Internist|January 30, 2013
[Acute myeloid leukemia. Genetic diagnostics and molecular therapy]R F Schlenk, K Döhner, H Döhner
Deutsche Medizinische Wochenschrift (1946)|October 12, 2012
[Novel therapeutic options in the treatment of BCR/ABL-negative myeloproliferative neoplasms]K Döhner, F Stegelmann, R F Schlenk, et al.
Blood|September 1, 1992
Contact-induced neutrophil activation by platelets in human cell suspensions and whole bloodA Ruf, R F Schlenk, A Maras, et al.
Bone Marrow Transplantation|May 9, 2000
Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT)M T Voso, S Martin, S Hohaus, et al.
Cancer Chemotherapy and Pharmacology|December 22, 1999
Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancerS Hohaus, S Martin, A Schneeweiss, et al.
Genes, Chromosomes & Cancer|July 4, 2001
Molecular-cytogenetic comparison of mucosa-associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tractT F Barth, M Bentz, F Leithäuser, et al.
Leukemia|June 25, 2011
Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroupsS C Lück, A C Russ, U Botzenhardt, et al.
Leukemia|July 18, 2001
Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemiaG Marcucci, M A Caligiuri, H Döhner, et al.
International Journal of Cancer|June 8, 2001
Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patientsA Seute, H P Sinn, R F Schlenk, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Der Internist|November 11, 2011
[Current treatment options in acute myeloid leukemia]M Heuser, R F Schlenk, A Ganser
Der Internist|January 30, 2013
[Acute myeloid leukemia. Genetic diagnostics and molecular therapy]R F Schlenk, K Döhner, H Döhner
Deutsche Medizinische Wochenschrift (1946)|October 12, 2012
[Novel therapeutic options in the treatment of BCR/ABL-negative myeloproliferative neoplasms]K Döhner, F Stegelmann, R F Schlenk, et al.
Blood|September 1, 1992
Contact-induced neutrophil activation by platelets in human cell suspensions and whole bloodA Ruf, R F Schlenk, A Maras, et al.
Bone Marrow Transplantation|May 9, 2000
Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT)M T Voso, S Martin, S Hohaus, et al.
Cancer Chemotherapy and Pharmacology|December 22, 1999
Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancerS Hohaus, S Martin, A Schneeweiss, et al.
Genes, Chromosomes & Cancer|July 4, 2001
Molecular-cytogenetic comparison of mucosa-associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tractT F Barth, M Bentz, F Leithäuser, et al.
Leukemia|June 25, 2011
Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroupsS C Lück, A C Russ, U Botzenhardt, et al.
Leukemia|July 18, 2001
Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemiaG Marcucci, M A Caligiuri, H Döhner, et al.
International Journal of Cancer|June 8, 2001
Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patientsA Seute, H P Sinn, R F Schlenk, et al.
Pageof 4